Hisamitsu Aims To Increase Profit By 30 Percent In Five Years
This article was originally published in PharmAsia News
Executive SummaryJapanese transdermal therapeutic patch maker Hisamitsu announced a five year mid-term plan to increase group business profit by 33.7 percent to ¥43.5 billion by 2014. The sales will mainly come from major product Salonpas, a pain relief patch series, which is planned to grow by 40 percent in market share. Hisamitsu also forecasts 30 percent growth in the athlete's foot remedy market. (Click here for more - Japanese language
You may also be interested in...
Analyzing Quality Data Is Essential. Here’s What One Expert Says Your Firm Should Do To Stay In FDA’s Good Graces
Device makers should make sure they have adequate resources to analyze quality data they take in so they can prevent the recurrence of nonconforming products, processes and procedures. That’s just one nugget of advice from former FDA investigations branch director Ricki Chase, who explains why collecting and properly handling such data is critical to complying with agency expectations in this Medtech Insight Q&A interview.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.